Nama's AI scorecard currently rates West Pharmaceutical Services Buy (7.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is WST's P/E ratio?

West Pharmaceutical Services trades at a trailing price-to-earnings ratio of 43.5.

When does WST report earnings?

West Pharmaceutical Services's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $2.28.

What is the WST price target?

The median analyst price target from 15 analysts is $480.00, with a range of $340.00 – $500.00.

Is WST Shariah compliant?

Nama's AAOIFI-style screen reads West Pharmaceutical Services as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does WST pay a dividend?

Yes — West Pharmaceutical Services's dividend yield is 0.3%.

Nama Insights

West Pharmaceutical Services (WST)

Healthcare · Medical Instruments Supplies · NYSE

S&P 500

West Pharmaceutical Services (WST) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $27.85B, a trailing price-to-earnings ratio of 43.5 and a free-cash-flow yield of 1.6%. Over the most recent reported fiscal year, revenue grew 6.2% and free cash flow per share grew 72.0%. Nama's AI scorecard rates it Buy, 7.1 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 7.1/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +33.1% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-15.8%

How far the last close sits under the highest price of the past five years.

Market cap	$27.85B
Trailing P/E	43.5
Price / book	9.4
Price / sales	8.2
FCF yield	1.6%
Dividend yield	0.3%
Gross margin	37.6%
Operating margin	22.5%
Net margin	18.8%
Revenue growth (YoY)	+6.2%
Revenue growth (3-yr annual)	+2.1%
EPS growth (YoY)	+8.0%
FCF/share growth (YoY)	+72.0%
Beta	1.1
Exchange	NYSE
Sector	Healthcare
Industry	Medical Instruments Supplies

WST earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate $2.28). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$2.66	$2.20	+20.9%	$874.50M
Q2 2026	Jul 23, 2026	$2.37	$2.08	+13.9%	$872.30M
Q1 2026	Apr 23, 2026	$2.13	$1.68	+26.8%	$844.90M
Q4 2025	Feb 12, 2026	$2.04	$1.83	+11.5%	$805.00M

WST analyst price target

Median target $480.00 from 15 analysts, ranging $340.00 – $500.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3
COO	Cooper Companies	$11.86B	13.5

Explore live WST data on Nama Insights →

Recent Congressional trades

West Pharmaceutical Services trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Rob Bresnahan	House	Sell	$1,001 - $15,000	May 8, 2025
Rob Bresnahan	House	Buy	$1,001 - $15,000	Mar 27, 2025
Jared Moskowitz	House	Sell	$1,001 - $15,000	Mar 6, 2025
Jared Moskowitz	House	Sell	$1,001 - $15,000	Dec 9, 2024
Jared Moskowitz	House	Buy	$1,001 - $15,000	Aug 21, 2024
Jared Moskowitz	House	Buy	$1,001 - $15,000	Aug 21, 2024
Jared Moskowitz	House	Buy	$1,001 - $15,000	Jan 22, 2024
Thomas R Tillis	Senate	Sell	$1,001 - $15,000	—

WST FAQ

Is WST a buy?: Nama's AI scorecard currently rates West Pharmaceutical Services Buy (7.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is WST's P/E ratio?: West Pharmaceutical Services trades at a trailing price-to-earnings ratio of 43.5.
When does WST report earnings?: West Pharmaceutical Services's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $2.28.
What is the WST price target?: The median analyst price target from 15 analysts is $480.00, with a range of $340.00 – $500.00.
Is WST Shariah compliant?: Nama's AAOIFI-style screen reads West Pharmaceutical Services as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does WST pay a dividend?: Yes — West Pharmaceutical Services's dividend yield is 0.3%.